Nuvo Research® is a specialty pharmaceutical company with a diverse portfolio of products and technologies.
Pennsaid 2% Out-Licensing Opportunity
The Company has received approval from the German BfArM to conduct a placebo controlled Phase 3 trial of Pennsaid 2% for the treatment of acute ankle sprains. The 124 patient trial will be conducted in Germany commencing early July of this year. Topline results are expected to be available in Q4 2015 or Q1 2016.The trial is intended to support regulatory applications for marketing approval of Pennsaid 2% in the E.U., Canada and certain other international territories. For further information regarding the Pennsaid 2% out-licensing opportunity – click here.
Nuvo Q3 2015 Results
Investor Presentation – November 23, 2015